VERX Stock Recent News

KING OF PRUSSIA, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a global provider of tax technology solutions, today announced that management will present at the following investor events:

Vertex Pharmaceuticals has a strong focus on cystic fibrosis, which is driving revenue growth and pipeline development. The company has outperformed Johnson & Johnson and the S&P 500 in terms of total returns. Near-term catalysts include advancements in CF treatment, pain treatment, sickle cell & beta thalassemia, type I diabetes, and IgA nephropathy.

Vertex has achieved significant growth in recent years, but things have slowed lately. The company has many potential catalysts that could accelerate its growth rate.

Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4, 2024 at 4:00 p.m. CT. Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific O.

Vertex, Inc. (NASDAQ:VERX ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Joe Crivelli – Vice President-Investor Relations David DeStefano – President and Chief Executive Officer John Schwab – Chief Financial Officer Conference Call Participants Chris Quintero – Morgan Stanley Daniel Jester – BMO Capital Joshua Reilly – Needham Adam Hotchkiss – Goldman Sachs Brad Reback – Stifel Natalie Howe – Bank of America Alex Sklar – Raymond James Austin Cole – Citizens Operator Greetings, and welcome to Vertex's First Quarter 2024 Earnings Conference Call. Please note this conference is being recorded.

KING OF PRUSSIA, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced preliminary financial results for the period ended March 31, 2024.

Vertex is recommended as a buy due to positive growth metrics and strong cross-selling abilities. Recent results show revenue and adjusted EBITDA beating expectations, with strong annual recurring revenue growth. FY24 guidance indicates accelerated subscription revenue growth and improved margins, supporting future growth.

Vertex, Inc. delivered better-than-expected EPS and net sales growth, leading to optimism in the market. The company operates in a large market with significant geographic diversification and a large market opportunity. Vertex's solid balance sheet, cloud offering, and integration with ERPs and CRMs position it for growth and scalability.

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.